Research ArticleArticle
Extraskeletal Manifestations in Axial Spondyloarthritis Are Associated With Worse Clinical Outcomes Despite the Use of Tumor Necrosis Factor Inhibitor Therapy
Rienk van der Meer, Suzanne Arends, Sandra Kruidhof, Reinhard Bos, Hendrika Bootsma, Freke Wink and Anneke Spoorenberg
The Journal of Rheumatology August 2021, jrheum.210308; DOI: https://doi.org/10.3899/jrheum.210308
Rienk van der Meer
The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.
Suzanne Arends
The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.
Sandra Kruidhof
The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.
Reinhard Bos
The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.
Hendrika Bootsma
The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.
Freke Wink
The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.
Anneke Spoorenberg
The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Extraskeletal Manifestations in Axial Spondyloarthritis Are Associated With Worse Clinical Outcomes Despite the Use of Tumor Necrosis Factor Inhibitor Therapy
Rienk van der Meer, Suzanne Arends, Sandra Kruidhof, Reinhard Bos, Hendrika Bootsma, Freke Wink, Anneke Spoorenberg
The Journal of Rheumatology Aug 2021, jrheum.210308; DOI: 10.3899/jrheum.210308
Extraskeletal Manifestations in Axial Spondyloarthritis Are Associated With Worse Clinical Outcomes Despite the Use of Tumor Necrosis Factor Inhibitor Therapy
Rienk van der Meer, Suzanne Arends, Sandra Kruidhof, Reinhard Bos, Hendrika Bootsma, Freke Wink, Anneke Spoorenberg
The Journal of Rheumatology Aug 2021, jrheum.210308; DOI: 10.3899/jrheum.210308